QCast Episode 57: Clinical Trial Performance Metrics

Clinical trial performance metrics can help study teams identify delays, assess operational processes and decide where follow-up is needed. In this QCast episode, co-hosts Jullia and Tom consider how sponsors and CROs can choose measures that support meaningful decisions, define them consistently and adapt their use across study start-up, conduct and closeout.

The practical challenge is rarely a lack of available data. Teams must decide which measures deserve attention, who owns the underlying process and how results should be interpreted when delivery depends on several parties. Poorly defined targets can create disputes or unintended incentives, while excessive reporting can conceal the measures that genuinely need action.

🎧 Listen to the Episode:

Key Takeaways

Choose metrics that lead to a decision

A useful metric measures a process or outcome that somebody can understand and act on. Key performance indicators should be limited to the measures most relevant to study oversight, rather than treating every available number as equally important. A smaller, well-defined set usually gives study leaders a clearer view of performance.

Define ownership without ignoring shared dependencies

Many trial milestones depend on input from the sponsor, CRO, sites and external providers. Database lock, for example, can be affected by data cleaning, coding decisions, medical review, external data receipt and sponsor responses. Clear definitions and ownership help teams investigate delays without assigning responsibility before the cause is understood.

Interpret results in their operational context

A metric rarely explains performance on its own. A low query count could reflect well-designed case report forms and clean data, or it could indicate that review is incomplete. Thresholds, historical comparisons, recent trends and the timing of the report all help determine whether a result needs investigation, escalation or no immediate action.

Full Transcript

Episode 57: Clinical Trial Performance Metrics

Jullia

Welcome to QCast, the show where biometric expertise meets data-driven dialogue. I’m Jullia.

Tom

I’m Tom, and in each episode, we dive into the methodologies, case studies, regulatory shifts, and industry trends shaping modern drug development.

Jullia

Whether you’re in biotech, pharma or life sciences, we’re here to bring you practical insights straight from a leading biometrics CRO. Let’s get started.

Tom

Clinical trials generate plenty of numbers, but performance metrics are meant to tell us whether the trial itself is running as intended. So what is it that separates a useful metric from another figure in a report?

Jullia

A useful metric has a clear purpose. It measures a process, team, site, or study activity that somebody can understand and act on. If the number changes but nobody knows what decision should follow, the team is collecting information rather than managing performance.

Tom

So where do key performance indicators fit? People often use KPI and metric as though they mean the same thing.

Jullia

Well a metric is any defined measurement. A KPI on the other hand is the smaller set selected because it matters most to oversight, governance, or a strategic study objective. What a lot of people don't realise is that treating every measure as a KPI can tend to bury the signals that study leaders actually need to see.

Tom

So you're saying that the instinct to measure everything can end up working against the team?

Jullia

Very easily, yes. See, each metric needs data collection, checking, reporting, interpretation, and often discussion in a meeting. A smaller set of accurate measures usually gives better oversight than some odd, large scorecard that nobody really has time to examine properly.

Tom

There’s a contractual side to this as well, particularly when a sponsor and CRO are sharing delivery. How do you stop performance metrics becoming a blame mechanism?

Jullia

By defining accountability honestly. Some outcomes sit mainly with the CRO, some with the sponsor, and many depend on both parties or on sites.

Tom

Could you give an example where ownership is shared?

Jullia

Take database lock timelines. The data management team may be responsible for cleaning and finalising the database, but unresolved coding decisions, late external data, pending medical review, or delayed sponsor responses can all affect the date. A well-defined metric makes those dependencies visible and gives the team a basis for resolving them earlier.

Tom

That also suggests the metric needs more than a title on a dashboard.

Jullia

Yes. It needs a precise definition, a start point, an end point, a data source, an owner, a reporting frequency, and an agreed target or range. Without those details, two teams can report the same named metric and still calculate different results.

Tom

The terms leading and lagging indicators come up a lot here. How would you explain the difference without making it theoretical?

Jullia

A leading indicator helps the team spot an opportunity to intervene in the current trial. A lagging indicator describes an outcome that has already happened and may guide future studies or process improvement. Both are useful, but they support different decisions.

Tom

Give me a leading indicator from day-to-day data management.

Jullia

The time from receiving a query response to updating the database is a good example. If that cycle time starts to lengthen, the team can look at workload, hand-offs, or prioritisation while the study is still active. They may find responses are sitting in a queue or moving through more people than the process requires.

Tom

Is there a risk that teams classify a metric neatly, then assume the label tells them what to do?

Jullia

There is. The classification is only helpful if it connects to an intended use. A lagging result can still trigger investigation, and a supposedly leading measure is weak if the report arrives too late for anybody to intervene.

Tom

Timing matters across the wider study lifecycle too, doesn't it. Should it be updated at key points throughout?

Jullia

The emphasis should. During start-up, teams may watch protocol-to-CRF timelines, site activation, contracting, and first patient first visit. During recruitment and conduct, attention often moves towards enrolment, visit completion, protocol deviations, monitoring activity, data entry, query ageing, and external data receipt. Near closeout, the focus shifts towards final cleaning, reconciliation, database lock, and reporting readiness.

Tom

A common misconception is that a single standard dashboard can be applied unchanged to every study. Is consistency still valuable?

Jullia

Consistency is valuable in definitions and calculation methods because it supports comparison across studies and programmes. The selected measures still need to reflect the study design, operational model, and important risks. A simple trial and a complex global study with several external data streams won’t need identical oversight.

Tom

There’s another issue to address. Once people know they’re being measured, behaviour can change. How should teams handle that?

Jullia

They need to look for unintended incentives. If a site or team is judged on one narrow target, people may optimise the number rather than the underlying process. That’s why measures should be reviewed together and interpreted with context, rather than used as isolated league tables.

For example, a very low query count might look good, but it could mean different things. It could reflect well-designed forms and clean data, or it might mean review is incomplete and queries aren’t being raised. The number of queries per hundred CRF pages only becomes useful when the team considers the protocol, edit checks, review status, site mix, and the types of queries being generated.

Tom

How should results be presented so busy study leaders can actually use them?

Jullia

Keep the display simple and make exceptions visible. A traffic-light dashboard can work well when the thresholds and definitions have already been agreed, but the colour isn’t the analysis. The team still needs to understand what changed, whether the data are reliable, and who will follow up.

Tom

Should every red result trigger an escalation?

Jullia

No. It should trigger the response agreed for that metric, which may be a closer review rather than an immediate escalation. Some variation is expected, and a raw number often needs a comparator such as the study plan, a historical study, an internal benchmark, or the recent trend.

Tom

Where does reporting frequency come into this?

Jullia

The cadence should match how quickly the process changes and how soon action is possible. Reporting too infrequently can conceal drift, while reporting too often creates noise and administration without adding insight. A twice-monthly start-up measure may be useful during site selection, whereas another operational measure may only need quarterly review.

Tom

You mentioned study risks earlier. How do performance metrics connect with quality by design?

Jullia

They can show whether the design and delivery choices are controlling the issues that matter to study quality. That could include missed key assessments, repeated protocol deviations, early terminations, delayed adverse event entry, or important data arriving too late for review. The measure should relate to a risk the team understands and can manage.

Tom

So if we were to close this out with a few takeaways, what should listeners carry into their next study planning or governance meeting?

Jullia

First, choose a small set of measures that support real decisions. Define each one clearly, including ownership, thresholds, cadence, and the action expected when performance moves out of range. And interpret results in context, especially where delivery depends on the sponsor, CRO, sites, and external providers working together.

When metrics are designed well, study teams see problems earlier, discuss them using shared definitions, and focus follow-up on processes that can actually be improved. The same information also supports a more useful review after the study, because the team can distinguish a one-off delay from a recurring weakness.

With that, we’ve come to the end of today’s episode on clinical trial performance metrics. If you found this discussion useful, don’t forget to subscribe to QCast so you never miss an episode and share it with a colleague. And if you’d like to learn more about how Quanticate supports data-driven solutions in clinical trials, head to our website or get in touch.

Tom

Thanks for tuning in, and we’ll see you in the next episode.

About QCast

QCast by Quanticate is the podcast for biotech, pharma, and life science leaders looking to deepen their understanding of biometrics and modern drug development. Join co-hosts Tom and Jullia as they explore methodologies, case studies, regulatory shifts, and industry trends shaping the future of clinical research. Where biometric expertise meets data-driven dialogue, QCast delivers practical insights and thought leadership to inform your next breakthrough.

Subscribe to QCast on Apple Podcasts or Spotify to never miss an episode.